Ann: Appendix 4E and Full Year Statutory Accounts, page-3

@Akki

Akki .. at the start of the Etiplersen trial in 2012, Sarepta was $3.90.. on 3 year trial results in October 2015, Sarepta traded at $38.00... on approval In September 2016 (after initial FDA rejection in April 2016) Sarepta traded at $62.00..

Bill and Gil were both there for the $1bn valuation which was actually achieved on the trial result alone.. on Approval, the market cap reached $3bn... so Sarepta gets a valuation of $1bn on the trial result showing bugger all, and ANP gets $50m on cracking data.. plenty of reasons for the difference.. Paradigm (PAR) has almost got the $1bn on pretty average but well promoted data..